| Literature DB >> 31803052 |
Hongtian Zhu1,2, Lei Tang1,2, Chenghong Zhang1,2, Baochu Wei1,3, Pingrong Yang1,4, Dian He1,4, Lifang Zheng1, Yang Zhang2,5.
Abstract
Chalcone derivatives, as a hot research field, exhibit a variety of physiological bioactivities and target multiple biological receptors. Based on the skeleton of (E)-1,3-diphenyl-2-propene-1-one, 14 chalcone derivatives were designed and synthesized, and evaluated as the antitumor candidates agents against four human cancer cell lines (A549, Hela, HepG2, and HL-60) as well as one normal cell line (WI-38). Among the title compounds, compound a14 showed better inhibitory activity against HepG2 cells (IC50 = 38.33 µM) and had relatively weak cytotoxicity towards normal cells WI-38 (IC50 = 121.29 µM). In this study, apoptosis, cycle arrest, assessment of reactive oxygen species (ROS) level, and measurement of mitochondrial membrane potential were adopted to explore the inhibitory mechanism of a14 towards HepG2. Compound a14 could effectively block the division of HepG2 cell lines in the G2/M phase and robustly induced generation of ROS, demonstrating that the generation of ROS induced by a14 was the main reason for resulting in the apoptosis of HepG2 cells. Moreover, the mitochondrial membrane potential (MMP) of HepG2 cells treated with a14 was significantly decreased, which was closely related to the enhanced ROS level. Furthermore, based on Western blot experiment, cell apoptosis induced by a14 also involved the expression of B-cell lymphoma-2 (Bcl-2) family and Caspase 3 protein. In summary, compound a14 could contribute to the apoptosis of HepG2 cells through regulating ROS-mitochondrial pathway, which provides valuable hints for the discovery of novel anti-tumor drug candidates.Entities:
Keywords: B-cell lymphoma-2; Caspase 3; HepG2 cell; chalcone; mitochondrial membrane potential; reactive oxygen species
Year: 2019 PMID: 31803052 PMCID: PMC6874057 DOI: 10.3389/fphar.2019.01341
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Scheme 1Synthesized compounds with different substituents.
Biological activities of target compounds towards different cell lines.
| Compds. | IC50 (µM) | ||||
|---|---|---|---|---|---|
| A549 | Hela | HepG2 | HL-60 | WI-38 | |
|
| 107.35 ± 2.14 | 125.34 ± 6.92 | 134.64 ± 9.79 | 130.71 ± 5.38 | 229.04 ± 7.38 |
|
| 82.46 ± 3.61 | 98.90 ± 2.90 | 76.96 ± 1.34 | 134.66 ± 2.45 | 122.2 ± 2.33 |
|
| 59.59 ± 5.23 | 77.61 ± 4.74 | 71.21 ± 4.63 | 141.38 ± 5.19 | 126.24 ± 0.46 |
|
| 48.17 ± 2.25 | 65.93 ± 7.80 | 46.41 ± 0.05 | 110.28 ± 2.04 | 100.24 ± 11.51 |
|
| 57.25 ± 1.53 | 82.19 ± 4.80 | 68.13 ± 5.51 | 107.83 ± 3.50 | 127.04 ± 6.60 |
|
| 51.34 ± 2.11 | 74.84 ± 2.33 | 75.41 ± 3.27 | 213.08 ± 2.98 | 109.48 ± 1.49 |
|
| 40.72 ± 3.68 | 40.72 ± 1.33 | 55.62 ± 3.23 | 111.35 ± 1.57 | 81.70 ± 1.13 |
|
| 64.95 ± 2.35 | 53.55 ± 0.67 | 57.35 ± 3.07 | 301.19 ± 3.53 | 147.31 ± 13.24 |
|
| 57.63 ± 1.42 | 65.07 ± 1.34 | 80.31 ± 1.87 | 210.14 ± 3.03 | 98.46 ± 4.91 |
|
| 45.55 ± 1.05 | 54.39 ± 1.11 | 70.80 ± 4.03 | 131.15 ± 4.64 | 93.28 ± 3.13 |
|
| 35.84 ± 1.02 | 48.23 ± 0.56 | 44.71 ± 1.56 | 245.00 ± 5.54 | 89.48 ± 6.61 |
|
| 41.22 ± 2.15 | 35.33 ± 2.13 | 54.37 ± 0.52 | 160.46 ± 3.59 | 122.98 ± 2.45 |
|
| 37.62 ± 1.11 | 31.82 ± 1.62 | 50.33 ± 4.03 | 134.43 ± 4.44 | 117.69 ± 3.53 |
|
| 36.70 ± 1.08 | 23.30 ± 2.35 | 38.33 ± 0.59 | 120.68 ± 3.58 | 121.29 ± 0.87 |
|
| 53.70 ± 1.16 | 35.21 ± 1.39 | 42.89 ± 2.88 | 165.13 ± 4.74 | 62.77 ± 2.03 |
IC50 values represent mean ± SE from at least three independent experiments.
Used as a reference.
Figure 1(A) Time and concentration-dependent effects of a14 on HepG2 cells’ growth and viability. Values are expressed as the means ± SE, by t test, n = 3, *P< 0.05, **P< 0.01, ***P< 0.001 compared with the group (cell growth inhibition rate in 0 µM); (B) Chemical structure of a14.
Figure 2Concentration dependent effects of a14 on HepG2 cell apoptosis. (A) HepG2 cells were stained with DAPI solution, and fluorescence microscope using a blue filter (magnification, 400×) was applied to observe the stained nuclei (red arrow indicating chromatin condensation); (B) Analysis of HepG2 cell apoptosis induced by a14 using Annexin V-Alexa Fluor 647/PI immunofluorescence labeling method; (C) Analysis of cell cycle arrest by PI staining assay after 24 and 48 h incubation with a14.
Figure 3Changes in ROS levels induced by a14 were probed by DCFH-DA in HepG2 cells. (A) Determination of fluorescence intensity in HepG2 cells under different conditions by flow cytometry; (B) Fluorescence intensity comparison chart with or without NAC; (C) Quantitative analysis of fluorescence intensity in HepG2 cells under different conditions; (D) Quantitative analysis of fluorescence intensity with or without NAC blockers; (E) Flow Cytometric analysis was applied to evaluate the pro-apoptosis of a14 (50 µM) on HepG2 cells for 48 h with or without the intervention of NAC (5 mM). Values are expressed as the means ± SE, by t test, n = 3, **P < 0.01, ***P< 0.001 vs. the black group (cell + DCF).
Figure 4(A) The relationship between MMP and a14 concentration in HepG2 cells; (B) The relationship between MMP and action time of a14 in HepG2 cells (CCCP, as the positive control, was used to completely deprive the MMP); (C) Flow cytometric analysis was applied to evaluate the effects on the MMP of a14 (50 µM) for 48 h with or without the intervention of NAC (5 mM).
Figure 5(A) Protein levels of Caspase 3, Bax, Bcl-2 in HepG2 cells; (B) Protein levels of PARP and CF-PARP proteins in HepG2 cells; (C) The relative protein level of Bax; (D) The relative protein level of Bcl-2; (E) The relative protein level of Caspase 3; (F) The relative protein level of PARP and CF-PARP. Values are expressed as the means ± SE, by t test, n = 3, *P< 0.05, **P< 0.01, ***P< 0.001 compared with the control.